MedTrace Logo

A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT05119335 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-11-12

No results posted yet for this study

Summary

The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.

Conditions

  • ccRCC
  • Clear Cell Renal Cell Carcinoma
  • Kidney Cancer
  • Kidney Neoplasms
  • Renal Cancer
  • Renal Neoplasms
  • Recurrent Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma
  • Refractory Renal Cell Carcinoma
  • Advanced Renal Cell Carcinoma
  • Hypoxia
  • Renal Cell Carcinoma
  • Hypoxia Inducible Factor (HIF)
  • HIF2α Inhibitor
  • Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha)
  • Hypoxia Inducible Factor 2α (HIF-2α)
  • Clear Cell

Interventions

DRUG

Oral NKT2152

Oral HIF2α inhibitor

Sponsors & Collaborators

  • NiKang Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-26
Primary Completion
2025-08-22
Completion
2025-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05119335 on ClinicalTrials.gov